McNicoll, Lewis & Vlak Reiterates Corcept Therapeutics Buy, $8 PT

McNicoll, Lewis & Vlak reiterated its Corcept Therapeutics CORT Buy rating and $8 price target in a research report published today. In the report, McNicoll, Lewis & Vlak states, "We have assumed that CORLUX will obtain US approval in 1H:12 and have conservatively assumed parity to generic mifepristone pricing for CORLUX ($0.50/mg). Moreover, we believe the ex-US market and potential off-label revenue in psychotic depression represents to upside to our present valuation." Shares of Corcept Therapeutics were trading at $2.79 at the time of posting, up 0.36% from Monday's market close.